Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α-Reference-Cited by-同舟云学术

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α

Published:2010-07 Issue:4 Volume:2 Page:428-439
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Shealy David J.,Cai Ann,Staquet Kim,Baker Audrey,Lacy Eilyn R.,Johns Laura,Vafa Omid,Gunn George,Tam Susan,Sague Sarah,Wang Dana,Brigham-Burke Mike,Dalmonte Paul,Emmell Eva,Pikounis Bill,Bugelski Peter J.,Zhou Honghui,Scallon Bernard J.,Giles-Komar Jill M.

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/mabs.12304

Reference40 articles.

1. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

2. TNFα blockade in human diseases: Mechanisms and future directions

3. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis

4. Tumor necrosis factor as a therapeutic target of rheumatologic disease

5. Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease

Cited by 205 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravenous Golimumab in the Treatment of Juvenile Idiopathic Arthritis and Its Associated Uveitis;Ocular Immunology and Inflammation;2024-08-29

2. Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases;Drug Discovery Today;2024-08

3. Efficacy of golimumab in rheumatoid arthritis patients at high risk of a poor prognosis: Post hoc analysis of GO-FORTH study using cluster analysis;Modern Rheumatology;2024-05-23

4. Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions;Clinical Pharmacology & Therapeutics;2024-03-15

5. Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets;Frontiers in Immunology;2024-01-04